Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk Rebounds After FDA Signals Crackdown on Copycat Drugs
07:36am, Friday, 06'th Feb 2026
Novo Nordisk (NVO) shares rebounded on Friday after comments from the head of the U.S. Food and Drug Administration (FDA) signaled a tougher stance on unapprove
Novo Nordisk Shares Rebound as FDA Moves Against Illegal Drug Copies
07:02am, Friday, 06'th Feb 2026
Shares of Novo Nordisk A/S (NVO, Financials) gained 4.7% after the U.S. Food and Drug Administration said it would crack down on companies marketing unapproved
Why Novo Nordisk stock fell 7% after a telehealth startup's announcement
05:41am, Friday, 06'th Feb 2026
Novo Nordisk's stock dove 7% on Thursday just after an announcement from a key competitor.
Envestnet Asset Management Inc. Sells 262,089 Shares of Novo Nordisk A/S $NVO
04:46am, Friday, 06'th Feb 2026
Envestnet Asset Management Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE: NVO) by 6.3% during the third quarter, according to the company in its most recent disclosure with the Securit
Novo Nordisk stock climbs out of hole on FDA chief's threat to block Hims and Hers pill
04:25am, Friday, 06'th Feb 2026
Novo Nordisk shares rallied on Friday in what's still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug.
Novo Nordisk shares rebound as FDA targets illegal drug copies
03:54am, Friday, 06'th Feb 2026
Shares in Danish drugmaker Novo Nordisk gained 4.7% in early trading on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to
Novo Nordisk A/S Q4 Earnings Call Highlights
01:36am, Friday, 06'th Feb 2026
Novo Nordisk A/S (NYSE: NVO) executives used the company's full-year 2025 earnings call to highlight continued growth in its GLP-1 franchises, a major new U.S. product launch with the Wegovy pill, and
Novo Nordisk A/S (NOVO:CA) Q4 2025 Earnings Call Transcript
10:54pm, Thursday, 05'th Feb 2026
Novo Nordisk A/S (NOVO:CA) Q4 2025 Earnings Call Transcript
Novo Nordisk has launched its Wegovy GLP-1 drug in pill form. Amazon is getting into the fight, offering ease and low costs to customers who buy the Wegovy pill on its platform.
New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.
Market Today: Amazon capex, AI selloff, Disney CEO shift
05:36pm, Thursday, 05'th Feb 2026
Stock News Amazon lifts 2026 capex to ~$200B: Amazon (AMZN) posted a Q4 EPS miss but revenue beat and guided 2026 capital expenditures to about $200 billion, pr
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
04:53pm, Thursday, 05'th Feb 2026
Hims and Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
Why a $49 weight-loss pill is rattling Novo Nordisk and Eli Lilly
02:29pm, Thursday, 05'th Feb 2026
Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide,
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
01:50pm, Thursday, 05'th Feb 2026
Bagsværd, Denmark, 5 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated p
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action
12:51pm, Thursday, 05'th Feb 2026
Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.
